Additionally, local RT did not improve the treatment outcomes when added to the co-administration of anti-PD-1/PD-L1 and anti-CTLA-4 antibodies in patients with NSCLC [148] and Merkel cell carcinoma [149]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.